This is a big approval for the company, given that Cobenfy doesn’t have the classic side effects seen in other antipsychotic ...

Bristol Myers Squibb, 2seventy bio to discontinue enrollment in phase 3 KarMMa-9 study of Abecma in patients with newly diagnosed MM: Princeton, New Jersey Friday, September 27, 2 ...

Bristol-Myers Squibb received FDA's approval for Cobenfy, which is poised to be a game changer in the treatment of ...

Pomerantz LLP is investigating claims on behalf of investors of 2seventy bio, Inc. ("2seventy bio" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or ...

and has since been joined by Carvykti as well as Bristol-Myers Squibb and bluebird bio rival CAR-T therapy Abecma (idecabtagene vicleucel). Tecvayli previously scored a priority medicines (PRiME ...

The U.S. Food and Drug Administration (FDA) on Thursday approved Cobenfy (xanomeline and trospium chloride), developed by ...

Analyst Evan Seigerman from BMO Capital maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) and increased the price ...

In a report released today, Srikripa Devarakonda from Truist Financial assigned a Buy rating to Bristol-Myers Squibb (BMY – Research Report). The company’s shares closed yesterday at $50.12.

The IAF will stop any arms transfers from Iran to Hezbollah and is ready to assist troops in any ground operations. Information ...

The indictment accuses the mayor of accepting and seeking “illegal campaign contributions to his 2021 mayoral campaign, as well as other things of value, from foreign nationals.” Hurubie Meko ...

Get the latest Australian and world news covering breaking news and trending topics that educate, engage and entertain. Learn more about where you live, the language you speak, and how the country ...

Big pharma's position in cancer cell therapies stems mainly from its $74 billion acquisition of Celgene, which added autologous CAR-T therapies Breyanzi (lisocabtagene maraleucel) for large B-cell ...